Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

eading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding our clinical goals, our plans for a clinical trial, the ability to conduct clinical trials sufficient to achieve positive completion, and the therapeutic and commercial value of the company's compounds. To the degree we are able to conduct clinical trials, we may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Forward-looking statements involve risks and uncertainties.  Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result o
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... our laptops and electric vehicles could store more energy ... help of a sponge-like silicon material. , Researchers ... used in one of the battery,s electrodes, as silicon ... of graphite. A paper describing the material,s performance as ... Nature Communications . , "Silicon has long been sought ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... device company that develops, manufactures and markets ... it will report selected,unaudited financial numbers including ... for the second fiscal quarter ended September ...
... Inc. ("Carna"),announced on October 27, 2008, the signing ... ("SUBC"). Under the terms of this,Agreement, SUBC will ... China., With China,s emergence as a strong ... companies have now established,research and production facilities in ...
... value and cost-effectiveness of spinal cord stimulation, ... BSX ) today welcomed an announcement by ... (NICE) recommending,the use of spinal cord stimulation (SCS) ... final guidance, NICE confirmed that,SCS is both safe ...
Cached Biology Technology:China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries 2China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries 3Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2UK's NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain 2UK's NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain 3UK's NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain 4UK's NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain 5
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... Physicists, chemists and engineers at the University of Pennsylvania ... of patchy particles, using charged, self-assembling molecules that may ... and perhaps be used in small batteries that store ... electrical charges of calcium ions just like the ...
... retinal prosthesis and fetal tissue transplant, restored some vision ... at Neuroscience 2009, the annual meeting of the Society ... news on brain science and health, may lead to ... an engineered protein restored vision in an animal model ...
... researchers from the United States, Korea, and France has sequenced ... E. coli bacteria, one used to study evolution ... practical applications. The findings will help guide future research and ... classical research that is the foundation of our understanding of ...
Cached Biology News:Penn team uses self-assembly to make molecule-sized particles with patches of charge 2Experimental treatments restore partial vision to blind people 2Genomes of 2 popular research strains of E. coli sequenced 2Genomes of 2 popular research strains of E. coli sequenced 3